Current Report Filing (8-k)
May 22 2015 - 9:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): May 19, 2015
Comission File
Number 333-154989
ENTEST
BIOMEDICAL, INC.
(Exact Name
of Company as Specified in Charter)
Nevada
|
26-3431263
|
(State or other jurisdiction
of incorporation or organization) |
(IRS Employer Identification
No.) |
|
|
4700
Spring Street, Suite 304, La Mesa California |
91942
|
(Address of principal
executive offices) |
(Zip Code) |
619-702-1404 |
(Company’s telephone number, including area code) |
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 3.02 Unregistered
Sales of Equity Securities
On May 19, 2015 Entest BioMedical,
Inc. ( the Company”) the Company issued 200,000,000 shares of the Company’s Common Stock ( “Shares”) to
the Sherman Family Trust in satisfaction of $20,000 of indebtedness owed to the Trust by the Company.
The Shares were issued pursuant
to Section 4(a) (2) of the Securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve
as placement agents for the sale. The shares were sold directly through our management. No commission or other consideration was
paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this
Offer and Sale of Shares.
SIGNATURE
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ENTEST BIOMEDICAL, INC. |
|
|
Dated: May 21, 2015 |
By: /s/ David Koos |
|
David Koos |
|
Chief Executive Officer |
Entest (CE) (USOTC:ETNI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Entest (CE) (USOTC:ETNI)
Historical Stock Chart
From Apr 2023 to Apr 2024